Popular
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CEGDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CEBeyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Project Oncology®On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
CardiologyTargeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Who Needs a TKI? Identifying the Right Candidates
MinuteCE®Who Needs a TKI? Identifying the Right Candidates
Programs
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CEGDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Project Oncology®On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Who Needs a TKI? Identifying the Right Candidates
MinuteCE®Who Needs a TKI? Identifying the Right Candidates
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology AcademyOCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology AcademyBeyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Clinical Practice
"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
The Convergence"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
- NEW EPISODE
Cracking the Code of Obstruction: Unmet Needs in oHCM
MinuteCE®Cracking the Code of Obstruction: Unmet Needs in oHCM
Treating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA
Medical Industry FeatureTreating Mild Cognitive Impairment in Alzheimer’s Disease: A Therapy’s 2-Way MOA
- NEW EPISODE
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®When ß-Blockers Fall Short in oHCM: Time for a New Approach?
- NEW EPISODE
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Doctors Lounge
"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
The Convergence"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
Messy Labs, Major Breakthroughs: The Happy Accidents That Shaped Modern Medicine
Rub Some Dirt In ItMessy Labs, Major Breakthroughs: The Happy Accidents That Shaped Modern Medicine
"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
The Convergence"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
Uncovering Disparities in Teleneurology Utilization Post-Pandemic
On the Frontlines of Multiple SclerosisUncovering Disparities in Teleneurology Utilization Post-Pandemic
“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
The Convergence“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
MS Management: Strategies for Ensuring Equitable Access to Teleneurology
On the Frontlines of Multiple SclerosisMS Management: Strategies for Ensuring Equitable Access to Teleneurology
CME
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
CME/CE Virtual EventRedefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
Turning Flares Into Function: Flag Uncontrolled Disease
MinuteCE®Turning Flares Into Function: Flag Uncontrolled Disease
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
MinuteCE®Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Industry Feature
Targeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Medical Industry FeatureTargeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Improving Outcomes and Reducing Delays in Orthopedic Surgery
Medical Industry FeatureImproving Outcomes and Reducing Delays in Orthopedic Surgery
Living with Psoriatic Arthritis: A Doctor-Patient Conversation
Medical Industry FeatureLiving with Psoriatic Arthritis: A Doctor-Patient Conversation
Neuroplasticity: A Potential Target for the Treatment of Depression
Medical Industry FeatureNeuroplasticity: A Potential Target for the Treatment of Depression
Groundbreaking AI Models Transform Cardiovascular Diagnosis
Medical Industry FeatureGroundbreaking AI Models Transform Cardiovascular Diagnosis
Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
Medical Industry FeatureTau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers